Good to compare... and this time it will be a % of a whole lot more op inc. Still equates to a 10% stock dilution if they do it ll the time.... to add to the options they have and the 400k options they added in in 2012 (promised to wait til 2015 before going back for more!). Still, this would not happen at all without Blueline being happy. They are in control and ..I suspect...looking for an exit.
Looking at the quote, apart from March, the stock has not been so low since 2003ish. So no change? Well... share count is double, so the market cap is double!
Businesses, though, are valued at about the same, since we have cash and equity of 150+ million vs... almost none 10 years ago. Also we should be at breakeven next few q's which are known to be slow ones - 10 yrs ago there were losses and dilution coming.
In 2014 co. will be in 4 potentially large markets, and even if stb market is no longer one where sigm can dictate pricing, major acceptance in one of the others would justify a much higher market cap. All down to a few design/program wins (except for z-wave), so it's an insiders' game. In the meantime, Z-wave should be spun off: it is hype time and shareholders deserve a ride!
Writing as one who though the Axxent deal was so great they bought in the first 5 min of trading after the announcement, I can tell you that post-split the RELATIVE valuation is almost exactly the same now as then.Sure stock price is up from 7ish to 11... but so to is the whole market...in addition we have debt instead of cash and far more very cheap options for CEO and management. So pretty much a wash. a new investor would have lost little compared to then and now has a lot more certainty of the market opportunities (listen to the recent webcast where Ferry did a good job for once).
Well, the potential for eps or a buyout is still there... if not improved. There has not been major dilution and the market cap is still tiny in absolute terms... for either business alone. Give them five years and this could be worth 500 million+...
And just lost a bit... though not much. Seems some knew earlier? than the market?? Still, this was the least likely to succeed trial. Triple breast is a better bet,but not if they can no longer attract patients.
I guess what you mean is January 2014!OR maybe after the SEC investigation (if that goes away so will the shareholder suit). But anyways the TKI pathway is very broad, hence many of the side-effects. TKIs are bad drugs, but tivo not as bad, so may be useful. Side-effects tend to sum up, so sutent is an awful drug to sue in combo. Still it is used... as is the pfizer drug closest to tivo.Neither drug is used in breast cancer... so is this good or bad for tivo? The other TKIs are barely used in CRC either, so no surprise tivo is "unlikely" to score there. BUT trial shows it is safe... so hopefully Astellas continues with tivo in "triple breast" trial... I suspect off-label use would be high, so ANY indication for tivo is worth more than usual?
Other than that, the 203 program proved news in late 2014... crowded filed there too. But 203 is said to be potent and is not that far behind the filed as in the case of tivo.
Low volume is even lower! Were they waiting for a higher price and dilute a little? I bought a little more based on the general positive developments... but hard to know what is going on. Guess the insiders like it that way! But they need to get on the Amex or back to nasdaq to allow many others to buy?
On its website datatrak claims to have been on the cloud before it was invented. Sticky cloud it seems... Based on margins, ONE is the least manual work-based, public anyways. What they need is the growth in backlog to convince the market that customers here want a cloud solutions. After that they can then re-ipo the company as the cloud-maker... and with the r/s still have a reasonable no of shares. Hard to imagine that this would be the only sector to not "go cloud".
How its done is then the question: did they r/s instead to lower no of shareholders,de-list and take it private in the meantime? Below from site anyway:
For more than a decade, DATATRAK has been pioneering eClinical technologies to safely accelerate drug, biologic and device development timelines. The Clinical Research Platform was built for The Cloud in 2000 when cloud technologies were referred to as ‘Internet-based’ systems. No clinical trial technology available today is as advanced or feature-rich as the new DATATRAK ONE™ software suite. With a new, more intuitive user interface providing improved workflows and mobility, the DATATRAK ONE™ Clinical Research Platform drives higher quality, enhances visibility and creates new efficiencies throughout the drug development process.
Sigma's z wave offers 3x range less power less complexity and less interference vs the bee. The bee is so close to wifi there is not the differentiation. So what, both work... the rest is marketing. Which is why z-wave,now proven, needs a bigger home.Spin-off please!
Because the market cap dropped by like 500k dollars? We need more shares... taking those we lost in the r/s and putting them in the hands of a "Vanguard/Wellington"... whatever it takes
Both stocks crashed end 2012 on the same day for the same reason: cloudy future! Somehow people lost faith in SREV last Fall .... but Larry has faith in the other... boosting returns to almost 5x the low.
Adept ipo'ed end 1995... by end of that financial year... some 6 months... market cap was 110 or so million. Adept's market cap is some 50% higher today, an a few weeks ago it was the same as in 1996! So, recent move may seem large, but in the bigger picture is not a huge move considering inflation and general stock dilution.Adept still addresses billion-dollar markets, is once again a first-mover in several categories and seems to have management team that knows what it is doing.Dilution due to need for cash...just w/c... is the only risk to valuation at the moment.
The rs will be 15x at least... given the criteria. 10 m xtra shares for new options is then 7% dilution - when fully reserved. Not SO many but they should earn them first! Incentives haven't worked so far as we can see. At least waiting time is short...
15 months ago they offered shares at one sixth of this price. Perhaps a measure of how prospects have changed.. or firmed up. Another way of looking at it was that that 50c was the last chance to get a big stake for a "friend or foe". Now all have an incentive for the stock price to go up.Next we see those results from depression trial.
I'll claim to be the longest poster here on IRE... and in that spirit tell that the renowned ECRI has listed it as one of 10 things for hospitals to consider: see below. We appear to be in great company, but given the history it is probably a negative... more anti-diffusion measures from the FDA in store?
Technologies and infrastructure issues on this year’s list include:
Copper surfaces in ICUs for preventing hospital-acquired infections
Computer-assisted sedation systems
Catheter-based renal denervation for treatment-resistant hypertension
Emergency departments designed just for elderly patients
Wearable powered exoskeleton rehabilitation for individuals with paraplegia
Magnetic resonance-guided focused ultrasound for cancer pain
NanoKnife® system to treat cancer
Real-time MRI adaptive radiation therapy
Intelligent pills to improve medication adherence and prevent readmissions
Well, now that I read the document... a small hatchet job. Still, IRE should be initially used ONLY when other methods cannot be used, are very risky or as salvage. All cancers of right size... whether rain , eye, liver or lung.. to name a few. Huge market. Nerve block is then not an issue... none are day surgeries. The WL 3 yrs ago came after some patient skipped a beat... surprise. Ango's fault of course. Hobbs was only good for the acquisition (if ever they get fda cancer indication approval), not the implementation.
A version of this was deleted y'day, yahoo can't stand links! So, briefly: Agosto makes a google loud-based security product for isns which should launch early this year. There is a video of it being demo'ed with (now) 7 views - look on ytube. Views are probably half mine! Demoed with Google glass, btw.
Last Dec., Flir paid some 50 m for a smaller Belgian competitor... making isns EV value of 15-20 m a joke. Of course, isns has the legal issue - with insurance and cash to take care of fall-out - but still? Is it the huge dependency on Econolite??
I guess ECRI could have mentioned that the FDA forced the removal of the planning software from the unit in the USA... which is one reason why pre-procedural planning takes more time and effort than otherwise. Ablation is just seconds though, not the (up to) hour+ for RFA in a large lesion.. or minutes fro MWA.
Given the general rise and the beta of a still small stock, I think this is not much more than "normal". Add to that, my first buys 10ish years ago have not gone up that much at all when annualized!
Look at QCOR to see when Broadwood starts to think enough is enough! First the scare... but then they hold their nerve and wait till the price recovers and sell only then.
Founded the same year, it would be fitting for that reason, too. Otherwise a perfect fit. Valeant stock has outperformed Staar just about every month for near 20 years except for last December (I'd say the only reason it looks like Staar performed better for longer was the Staar dip back in May of 2012). So relatively speaking, as a stock deal, you could argue Staar has never been cheaper than in November 2013. Valeant's ambition made up for most of Dec gains in 2 days!
In fact Valeant talked up the market cap by 3 billion, which leaves room for a 1+ billion bid for Staar! If all turns out well for Staar the stock price might start to run away from Valeant in 2016 anyway. Though history says bet on VRX.
Chitty Group downgraded the stock on the 8th... but raised the price target 25% to 26 dollars. Bit behind the graph there? Interesting that the investors believe the story more than the analysts.